Interest of High-throughput Sequencing of RNAs for the Diagnosis of Heterogeneous Genetic Diseases
1 other identifier
observational
15
1 country
1
Brief Summary
The advent of high throughput genomic DNA sequencing has led to major advances in the diagnosis of genetic diseases of heterogeneous origin. Thus, our hospital laboratory has developed in recent years several diagnostic tests based on the targeted sequencing of coding sequences of gene panels (from about twenty genes for DNA repair diseases to nearly five hundred genes for the intellectual disability). These targeted analyzes, carried out by capture, have thus solved 25 to 80% of the cases according to the indications, without allowing the diagnosis of the totality of the patients. For these negative cases, the search for mutations in the coding sequences was then extended to Whole Exome Sequencing, thus providing several additional diagnoses. Patients still remain without diagnosis after this exome study. These could be complex cases of genetic or even non-genetic origin, but also monogenic pathologies linked to mutations that are not identifiable by coding sequence analyzes, and especially affecting messenger RNAs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 31, 2019
CompletedStudy Start
First participant enrolled
June 1, 2019
CompletedFirst Posted
Study publicly available on registry
June 3, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2022
CompletedJune 3, 2019
May 1, 2019
1 month
May 31, 2019
May 31, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
RNA sequencing
testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing of coding regions, and its integration into hospital routine in order to improve the diagnosis of heterogeneous genetic diseases.
3 years
Study Arms (2)
Validation phase
The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
Prospective phase
The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
Interventions
Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
Eligibility Criteria
Patient suffering from a pathology studied in the laboratory by high throughput sequencing: intellectual disability, myopathies, neurosensory disease (Bardet-Biedl syndrome, retinitis pigmentosa, ....), DNA repair diseases (Cockayne syndrome, ...)
You may qualify if:
- Patient minor or major
- Patient suffering from a pathology studied in the laboratory by high throughput sequencing: intellectual disability, myopathies, neurosensory disease (Bardet-Biedl syndrome, retinitis pigmentosa, ....), DNA repair diseases (Cockayne syndrome, ...)
- Sampling allowing the extraction of available RNA (or RNA available in the bank)
- Patient (or its legal representative) having already given their consent, on the one hand for carrying out genetic analyzes to determine the cause of their disease, and on the other hand for the conservation of part of their non used for further use in order to continue diagnostic investigations in the light of evolving knowledge and for research purposes.
- Patient (or its legal representative) agreeing to use data from his medical file and those associated with genetic diagnosis for research purposes
- Magnetic molecular diagnosis, after the usual investigations (high-throughput sequencing of a panel of genes on genomic DNA, sequencing of exome, or even genome.
- ◾ Refusal of the patient (or his / her legal representative) to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 31, 2019
First Posted
June 3, 2019
Study Start
June 1, 2019
Primary Completion
July 1, 2019
Study Completion
July 1, 2022
Last Updated
June 3, 2019
Record last verified: 2019-05